Skip to content

Study · Systematic review · 2023

6 results

Effects of GLP-1 receptor agonists on neurological complications of diabetes.

García-Casares N, González-González G, de la Cruz-Cosme C, Garzón-Maldonado FJ, de Rojas-Leal C, Ariza MJ, Narváez M, Barbancho MÁ, García-Arnés JA, Tinahones FJ

Reviews in endocrine & metabolic disorders26 May 2023Cited by 34 (Europe PMC)

PMID37231200 (opens in a new tab)PMCIDPMC10404567 (opens in a new tab)DOI10.1007/s11154-023-09807-3 (opens in a new tab)PepBankPUB-37231200
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy. We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy. Semaglutide subcutaneous and dulaglutide reduced stroke cases. Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events. Exenatide, dulaglutide and liraglutide improved general cognition but no significant effect on diabetic peripheral neuropathy has been reported with GLP-1 RAs. GLP-1 RAs are promising drugs that seem to be useful in the reduction of some neurological complications of diabetes. However, more studies are needed.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in diabetes, subcutaneous semaglutide reduced stroke cases.

    In plain wordsIn a review of diabetes trials, subcutaneous semaglutide reduced the number of strokes.

    Peptide
    Semaglutide
    Outcome
    DecreaseStroke
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Semaglutide subcutaneous and dulaglutide reduced stroke cases.
    2 context sentences
    Summary · context
    We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy.
    Summary · context
    We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in diabetes, oral semaglutide was not shown to reduce the number of strokes.

    In plain wordsIn a review of diabetes trials, oral semaglutide was not shown to reduce strokes.

    Peptide
    Semaglutide
    Outcome
    No significant changeStroke
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events.
    2 context sentences
    Summary · context
    We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy.
    Summary · context
    We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.
  3. 03HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in diabetes, oral semaglutide reduced major cardiovascular events.

    In plain wordsIn a review of diabetes trials, oral semaglutide reduced major cardiovascular events.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor cardiovascular events
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events.
    2 context sentences
    Summary · context
    We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy.
    Summary · context
    We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.
  4. 04HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in diabetes, liraglutide was not shown to reduce the number of strokes.

    In plain wordsIn a review of diabetes trials, liraglutide was not shown to reduce strokes.

    Peptide
    Liraglutide
    Outcome
    No significant changeStroke
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events.
    2 context sentences
    Summary · context
    We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy.
    Summary · context
    We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.
  5. 05HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in diabetes, liraglutide reduced major cardiovascular events.

    In plain wordsIn a review of diabetes trials, liraglutide reduced major cardiovascular events.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor cardiovascular events
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events.
    2 context sentences
    Summary · context
    We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy.
    Summary · context
    We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.
  6. 06HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in diabetes, liraglutide improved general cognition.

    In plain wordsIn a review of diabetes trials, liraglutide improved general cognition.

    Peptide
    Liraglutide
    Outcome
    IncreaseGeneral cognition
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide, dulaglutide and liraglutide improved general cognition
    2 context sentences
    Summary · context
    We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy.
    Summary · context
    We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07030621

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

RenJi Hospitaln = 436est. 1 Jul 2025 to est. 31 Jan 2028

Acute Ischemic Stroke

Trial pageClinicalTrials.govUpdated 22 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    27 Oct 2026, 16:32 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.